Uncategorized

XERS – Bull Case Shows 217% Upside while Bear Case Shows 42% Upside

The tl;dr is that a bull case evaluation for XERS shows an upside of 217% with PT $14.21 and a bear case evaluation shows an upside of 42% with PT $6.38. Note that this does not factor in the possibility of a short squeeze which could increase the price past its fundamental value. Given the…

An Undeserved Valuation: Xeris Pharmaceuticals

Source: Fortune Team | Jan 23 | Updated: Jan 24 | Blatantly undervalued and under-followed, Xeris has the potential to shine significantly in 2021, ascending as a true Fortune Alert( alerted initially in $2s). Take a look at our thoughts in a nutshell: Overview Xeris is a specialty pharmaceutical company that offers bold, innovative formulation technologies:…

The Next GameStop? 25 Stocks With High Short Interest

Source: Kiplinger | by: Dan Burrows June 11, 2021 A recent trading frenzy around heavily shorted stocks has targeted names such as these. But beware: The music could stop at any moment. Meme stocks are back in the headlines in a big way these days, with shares in everything from GameStop (GME, $220.39) to AMC Entertainment (AMC, $42.81) to Clover Health…

BMO Short Update

Source: Twitter @_B_I_O_T_E_C_H_

A Bull Case Valuation for $XERS

Written by https://twitter.com/ex_kuhlo.  The below is his opinion, not his advice.   Xeris is a commercial stage small biotech company which recently announced the takeover of Strongbridge Biopharma ($SBBP).Currently Xeris sells the Gvoke Hypopen for use with Hypoglycemia. Hypoglycemia is a serious, possibly deadly condition where blood glucose levels of diabetes patients are too low. Until…

  • 1
  • 2